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Abstract: Nonalcoholic fatty liver disease (NAFLD) emerges as an important global burden and
Helicobacter pylori infection (Hp-I) has been suggested as a risk factor of NAFLD, although controversy
exists. This retrospective study aimed to investigate a potential impact of active Hp-I on NAFLD
severity in morbidly obese patients, subjected to bariatric surgery and gastric biopsy for documentation
of Hp-I. Of 64 eligible participants, 15 (23.4%) were diagnosed with active Hp-I, showing higher rates
of nonalcoholic steatohepatitis (NASH) than those without Hp-I (86.7% vs. 26.5%, respectively; p <
0.001). Concerning histological lesions, steatosis grade (p = 0.027), ballooning (p < 0.001), lobular
inflammation (p = 0.003), and fibrosis stage (p < 0.001) were also more severe in Hp-I positive
patients. Likewise, liver function tests, insulin resistance, dyslipidemia, and arterial hypertension
were significantly higher in Hp-I positive patients. Hp-I was independently positively associated with
NASH (beta = 3.27; p = 0.002), severe NASH (beta = 2.37; p = 0.018), and the presence of fibrosis
(beta = 3.86; p = 0.001) in a binary regression model, after adjustment for potential confounders. In
conclusion, active Hp-I was independently associated with NASH and fibrosis, findings offering
potential clinical implication.
Keywords: nonalcoholic steatohepatitis; NASH; NAFLD; nonalcoholic fatty liver disease; Helicobacter
pylori; Hp; metabolic syndrome; MetS
1. Introduction
Nonalcoholic fatty liver disease (NAFLD), as the hepatic component of the metabolic syndrome
(MetS), represents a leading cause of chronic liver disease; its estimated global prevalence is about
25% of the general population [1] whereas in morbidly obese individuals its prevalence might rise
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up to 90% [1,2]. NAFLD is bidirectionally linked to MetS and insulin resistance (IR) [3]. The general
term NAFLD encompasses a spectrum of distinct pathologies; simple steatosis (nonalcoholic fatty liver,
NAFL) represents a reportedly benign entity, but might progress in a percentage of patients after the
effect of “multiple hits” [2–4], to nonalcoholic steatohepatitis (NASH), which may also progress to
fibrosis, liver cirrhosis, and hepatocellular carcinoma [3].
One of the potential pathogenetic “multiple hits, is regarded to be Helicobacter pylori infection
(Hp-I) [1], with an estimated prevalence of 58% (varying from 39.9%–91.7%) worldwide [5]. Hp-I
exhibits pleiotropic local and systematic manifestations. Peptic ulcer, nonulcer dyspepsia, gastric
adenocarcinoma, gastric mucosa-associated lymphoid tissue lymphoma, and colorectal cancer belong
to its classical pathogenicity [6,7]. Beyond its established local pathologies, Hp-I has been associated
with systematic entities, including MetS, IR, diabetes mellitus type 2 (T2DM), coronary artery disease,
and neurodegenerative diseases [1,8]. In addition, there is accumulating evidence, that Hp-I might
contribute to the development and progression of NAFLD, as concluded in several studies [9–13],
although controversy still exists [14–16], as we have previously systematically reviewed [1]. Notably,
meta-analyses, having been conducted on the association between Hp-I and NAFLD, showed higher
rates of NAFLD in Hp infected individuals, as we have also reviewed [5].
Together with the aforementioned high prevalence of NAFLD in morbidly obese individuals,
the prevalence of Hp seropositivity in these patients is also higher (a 1.7-fold increased probability of
having Hp-I) compared with nonobese controls [17]. However, the serological test does not discriminate
between active and past infection. Beyond serological testing for Hp-I, there are further diagnostic
modalities used for the investigation of a possible association between Hp-I and NAFLD: Urea breath
test [18–23] and the detection of Hp antigen in patients’ stool [24] for the diagnosis of Hp-I, as well
as sonography [10,19,23–26], and liver function tests and various noninvasive indices [10,11,22,27]
for the diagnosis of NAFLD. Nevertheless, 13C urea breath and Hp antigen fecal tests are also not
sufficient to substitute the histological diagnostic “gold standard” for detection of active Hp-I; the gold
standards for the diagnosis of Hp-I and NAFLD are currently histological examination after gastric
and liver biopsies, respectively [28–31]. However, studies with gastric and liver biopsies are currently
scarce [14].
The aim of this study was to investigate a potential association of active Hp-I with NAFLD and its
histological severity in morbidly obese patients subjected to bariatric surgery, gastric, and liver biopsy.
2. Methods
2.1. Study Design
The study was performed retrospectively, using an electronic database with 94,304 case records
of patients who have been presented to the emergency department (ED) of Inselspital Bern from 1
January 2017 to 30 November 2018. This academic hospital offers its medical services to an area of
approximately 2,000,000 citizens.
2.2. Ethical Considerations
The last revision of the principles of the Declaration of Helsinki was fulfilled. The study was
approved by the cantonal (district) ethics committee in Berne, (Kantonale Ethikkommission Bern, Ref.
No. KEK-BE: 010/2016) and since our patients were fully anonymized prior to analysis, according to
Swiss law, informed consent was not mandatory.
2.3. Inclusion and Exclusion Criteria
Eligible were morbidly obese patients older than 16 years having been subjected to bariatric
surgery, as well as to liver and gastric biopsy for documentation of NAFLD and active Hp-I, respectively.
Exclusion criteria were: Ethanol consumption (>20 g/day); previous Hp eradication treatment; known
history of other active or past hepatobiliary disease; history of gastrectomy; malignancies; inappropriate
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thyroid or adrenal function; kidney disease; pregnancy or lactation; use of glucocorticoids, insulin,
orlistat, methotrexate, amiodarone, vitamin E, pioglitazone, intravenous glucose, or parenteral nutrition
administration; any drug addiction; type 1 DM; pancreatitis; thrombotic disorders. Patients with
T2DM were excluded if they were on thiazolidinediones or insulin treatment.
2.4. Data Collection and Extraction
Morbidly obese patients undergoing an elective bariatric operation were recruited. Specifically,
the Hp-I status was evaluated by the diagnostic “gold standard” histology from gastric biopsies,
obtained either preoperatively (in terms of a routine esophagogastroduodenoscopy) or intraoperatively.
Histological diagnosis of Hp gastritis was made on 5 µm formalin-fixed, paraffin-embedded tissue
sections by means of Hematoxylin and Eosin staining. A modified Giemsa stain was also used to
highlight the Hp bacteria.
Liver specimens were obtained intraoperatively during laparoscopic bariatric surgery, from liver
segment II or, less commonly, segment III. Grading and staging of NAFLD was based on the NASH
Clinical Research Network scoring system [32]; for the discrimination between NAFL and NASH, both
NAFLD activity score (NAS) [32] and fatty liver inhibition of progression (FLIP) were used, the latter
introduced in morbidly obese populations [29]. Severe NASH was defined as steatosis, activity, and
fibrosis (SAF) scoring system ≥3 and/or F ≥ 3, as elsewhere recommended [33].
Patients’ records at the time of admission to the ED were stored in the clinical application E.care for
Windows (E.care BVBA, ED 2.1.3.0, Turnhout, Belgium). E.care offers the advantage of instantaneous
recall of medical reports, and other relevant data, while multiple filters of E.care application can be
applied. Patients’ records from ED were extracted to an Excel sheet (Microsoft® Excel for Mac 2019,
Microsoft Corporation, Redmond, WA, USA) with the use of appropriate filters. Eligibility of the
retrieved patients was evaluated by two investigators (M.D. and S.S.), following the inclusion and
exclusion criteria. Selected data were validated by D.S.S. In cases of conflict, a consensus was met by
the intervention of a senior author (A.E.). The following parameters were extracted: (a) Demographics
and anthropometric (age, gender, body-mass index (BMI)); (b) histological findings of gastric and
liver biopsies: Hp-I positivity, steatosis grade, lobular inflammation, ballooning degeneration, and
fibrosis; (c) MetS components, i.e., IR, dyslipidemia, hypertension, and T2DM, as recommended by the
Expert Committee on the Diagnosis and Classification of Diabetes [34]; in this regard, dyslipidemia
was defined as triglyceride levels ≥150 mg/dL (1.7 mmol/L) or LDL-C levels ≥ 100–160 mg/dl (2.58–4.13
mmol/L, depending on other risk factors) or HDL-C levels < 40 and 50 mg/dl (1.03 and 1.29 mmol/L) in
men and women, respectively, or treatment with hypolipidemic medication(s); arterial hypertension
was defined as systolic blood pressure≥ 130 mmHg or diastolic blood pressure≥ 85 mmHg or treatment
with antihypertensive medication(s); (d) laboratory tests: Fasting glucose and fasting insulin (for the
calculation of IR, using the homeostasis model assessment IR (HOMA-IR) [35]), glycated hemoglobin
A1c (Hba1c), liver function tests (aspartate aminotransferase (AST), alanine aminotransferase (ALT),
gamma-glutamyl transferase (GGT), bilirubin).
2.5. Statistical Analysis
Data are presented as mean ± standard deviation (SD) and percentages, for continuous and
categorical variables, respectively. The normality of distributions of continuous variables was tested
with the Kolmogorov–Smirnov test. The comparisons of continuous and categorical variables were
performed with the Mann–Whitney test and chi-square test (or the Fischer exact test), respectively.
Binary logistic regression analysis was performed to investigate whether Hp-I was independently
associated with NASH, severe NASH and fibrosis, because they are considered the main histological
endpoints. As independent variables, we entered parameters related to MetS (BMI, hypertension,
dyslipidemia, HOMA-IR), as well as age and gender. Statistical analysis was performed with SPSS 21.0
for Macintosh (IBM Corp., Armonk, NY, USA). Significance was set at p < 0.05 (two tailed).
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3. Results
Sixty-four patients (47 women), subjected to both gastric and liver biopsy, were recruited in this
study. Fifteen (23.4%) patients were positive for Hp-I. According to the FLIP algorithm, nine (14.1%)
patients were classified as “No NAFLD”, 29 (45.3%) as NAFL, and 26 (40.6%) as NASH. Severe NASH
was observed in 13 (20.3%) patients. According to NAS, eight (12.5%) patients were classified as “No
NAFLD”, 25 (39.0%) as NAFL, 17 (26.6%) as borderline NASH, and 14 (21.9%) as definite NASH.
Regarding fibrosis stage, 39 (61.0%) patients were at F0, 18 (28.1%) at F1, 5 (7.8%) at F2, 2 (3.1%) at F3,
whereas none were at F4; due to the small number of patients at F3, categories F2 and F3 were merged
for the analysis (F2/3: 7 (10.9%) patients).
Comparative data between Hp-I positive [Hp(+)] and negative [Hp(−)] patients are presented
in Table 1. Hp(+) and Hp(−) groups were of similar gender age, and BMI. AST, ALT, GGT, bilirubin,
triglycerides, and HOMA-IR were higher in Hp(+) than in Hp(−) group, whereas total cholesterol,
HDL-C, and LDL-C were not statistically different between groups. Higher rates of hypertension (p
= 0.041) and triglyceridemia (p = 0.039), but not prediabetes/diabetes, were observed in Hp(+) than
Hp(−) group. Regarding both FLIP and NASH classifications, higher rates of NASH were observed
in Hp(+) than in Hp(−) group (Table 1). Likewise, higher rates of severe NASH were observed in
Hp(+) than in Hp(−) group. Concerning separate histological lesions, histological severity was more
prominent in Hp(+) than Hp(−) patients in steatosis grade, ballooning, lobular inflammation, and
fibrosis (Table 1, Figure 1). Representative histological images from the included patients are illustrated
in Figure 2. When the analysis was repeated in women (n = 47), the results remained essentially
unchanged. However, the analysis in men was avoided, mainly owing to the small sample of men
(n = 17), which might have led to insecure conclusions.
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Figure 1. Bar grams depicting the histological endpoints: (a) FLIP; (b) NAS; (c) steatosis grade; (d)
ballooning; (e) lobular inflammation; (f) fibrosis stage. The rates of Hp infection were increased with
the severity of all presenting histological lesions and composite scores (FLIP and NAS). Hp(+): Black
bars; Hp(−): Grey bars. Abbreviations: F: Fibrosis stage; FLIP: Fatty liver inhibition of progression;
Hp(+): Helicobacter pylori positive; Hp(−): Helicobacter pylori negative; NAFLD: Nonalcoholic fatty liver
disease; NAS: Nonalcoholic fatty liver disease activity score; NASH: Nonalcoholic steatohepatitis.
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Table 1. Comparative data between Hp(+) and Hp(−) patients.
Hp(−)
N = 49 (76.6%)
Hp(+)
N = 15 (23.4%) p-Value *
Women [N (%)] 37 (75.5) 10 (66.7) 0.52
Age (years) 46.7 ± 13.3 49.1 ± 12.4 0.51
BMI (kg/m2) 45.5 ± 10.2 42.6 ± 5.9 0.70
AST (U/L) 24.5 ± 9.0 42.7 ± 18.9 0.001
ALT (U/L) 28.6 ± 20.5 51.6 ± 24.5 <0.001
GGT (U/L) 35.7 ± 43.9 86.3 ± 60.2 <0.001
Bilirubin (µmol/L) 7.8 ± 5.2 12.2 ± 8.3 0.013
Triglycerides (mmol/L) 1.48 ± 1.58 2.02 ± 0.98 0.003
Total cholesterol (mmol/L) 4.39 ± 1.14 4.79 ± 0.46 0.10
HDL-C (mmol/L) 1.29 ± 0.37 1.23 ± 0.46 0.55
LDL-C (mmol/L) 2.48 ± 0.85 2.72 ± 0.64 0.20
HbA1c (%) 5.7 ± 0.6 6.0 ± 1.3 0.33
HOMA-IR 4.3 ± 3.9 10.1 ± 6.8 <0.001
Prediabetes/Diabetes [N (%)] 24 (49.0) 9 (60.0) 0.46
Arterial hypertension [N (%)] 18 (36.7) 10 (66.7) 0.041
FLIP [N (%)] <0.001
No NAFLD 9 (18.4) 0 (0.0)
NAFL 27 (55.1) 2 (13.3)
NASH 13 (26.5) 13 (86.7)
Severe NAFLD [N (%)] 6 (12.2) 7 (46.7) 0.008
NAS [N (%)] 0.001
No NAFLD 8 (16.3) 0 (0.0)
NAFL 24 (49.0) 1 (6.6)
Borderline NASH 10 (20.4) 7 (46.7)
Definite NASH 7 (14.3) 7 (46.7)
Steatosis [N (%)] 0.027
Grade 0 9 (18.4) 0 (0.0)
Grade 1 22 (44.9) 3 (20.0)
Grade 2 11 (22.4) 7 (46.7)
Grade 3 7 (14.3) 5 (33.3)
Ballooning [N (%)] <0.001
0 28 (57.1) 1 (6.6)
1 20 (40.8) 10 (66.7)
2 1 (2.0) 4 (26.7)
Lobular inflammation [N (%)] 0.003
0 30 (61.2) 2 (13.3)
1 13 (26.5) 7 (46.7)
2 6 (12.2) 6 (40.0)
Fibrosis stage [N (%)] <0.001
F0 37 (75.5) 2 (13.3)
F1 11 (22.4) 7 (46.7)
F2/3 1 (2.0) 6 (40.0)
Data are presented as mean ± standard deviation (SD) for continuous, and frequencies (percentage) for categorical
variables. * Between group comparisons (Mann–Whitney test for continuous and chi-square or Fischer exact test for
categorical variables). Abbreviations: ALT: Alanine transaminase; AST: Aspartate transaminase; BMI: Body mass
index; FLIP: Fatty liver inhibition of progression; GGT: Gamma-glutamyl transferase; HbA1: Glycated hemoglobin;
HDL: High density lipoprotein; HOMA-IR: Homeostatic model of assessment insulin resistance; LDL: Low density
lipoprotein; NAFLD: Nonalcoholic fatty liver disease; NAS: Nonalcoholic fatty liver disease activity score; NASH:
Nonalcoholic steatohepatitis.
Binary regression analysis was performed with FLIP as dependent variable in a subset of patients
(NALF vs. NASH; n = 55), after the exclusion of those without NAFLD (n = 9). The results of this
analysis are presented in Table 2. NASH remained independently positively associated with Hp-I
(p = 0.002) after adjusting for potential confounding. Next, regression analysis was performed with
severe NASH as dependent variable (No vs. Yes) in the sum of patients. Again, severe NASH remained
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independently positively associated with Hp-I (p = 0.018; Table 3). In this model, age and BMI were also
independently positively associated with severe NASH. Likewise, when fibrosis (F0 vs. F1-3) in the
sum of patients was selected as dependent variable, the presence of fibrosis remained independently
positively associated with Hp-I (p = 0.001; Table 4). In this model gender was also independently
associated with the presence of fibrosis (i.e., men had independently higher risk of fibrosis).J. Clin. Med. 2020, 9, x FOR PEER REVIEW 5 of 14 
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Figure 2. Liver microphotographs of patients with the most representing stages of nonalcoholic
fatty liver disease. (A) Formalin fixed, paraffin embedded histological section (hematoxylin and
eosin staining) of liver with normal architecture. (B) Formalin fixed, paraffin embedded histological
section (hematoxylin and eosin staining) of liver with prominent steatosis without activity or fibrosis.
(C) Formalin fixed, paraffin embedded histological section (Masson trichrome staining) of liver with
bridging fibrosis.
Table 2. Independent associates of NASH (NAFL vs. NASH), according to FLIP classification in binary
logistic regression analysis.
Independent Variables Beta Exp(Beta) p-Value 95% CI for Exp(Beta)
Hp-I diagnosis
(0: Negative; 1: Positive) 3.27 26.32 0.002 3.36–206.23
Gender
(0: Women; 1: Men) 1.30 3.68 0.14 0.65–20.73
Hypertension
(0: No; 1: Yes) −1.17 0.31 0.19 0.05–1.80
Hyperglyceridemia
(0: No; 1: Yes) −0.33 0.72 0.70 0.14–3.75
Age (years) 0.03 1.03 0.40 0.97–1.09
BMI (kg/m2) 0.05 1.06 0.15 0.98–1.14
HOMA-IR 0.15 1.17 0.12 0.96–1.41
Abbreviations: BMI: Body mass index; FLIP: Fatty liver inhibition of progression; HOMA-IR: Homeostatic
model of assessment insulin resistance; Hp-I: Helicobacter pylori infection; NAFL: Nonalcoholic fatty liver; NASH:
Nonalcoholic steatohepatitis.
Table 3. Independent associates of severe NASH (No vs. Yes), according to FLIP classification in binary
logistic regression analysis.
Independent Variables Beta Exp(Beta) p-Value 95% CI for Exp(Beta)
Hp-I diagnosis
(0: Negative; 1: Positive) 2.37 10.73 0.018 1.50–76.46
Gender
(0: Women; 1: Men) 0.06 1.06 0.95 0.17–6.58
Hypertension
(0: No; 1: Yes) 0.06 1.07 0.94 0.20–5.74
Hyperglyceridemia
(0: No; 1: Yes) 0.44 1.56 0.62 0.27–9.09
Age (years) 0.09 1.10 0.028 1.01–1.19
BMI (kg/m2) 0.10 1.10 0.035 1.01–1.21
HOMA-IR 0.02 1.02 0.82 0.88–1.17
Abbreviations: BMI: Body mass index; FLIP: Fatty liver inhibition of progression; HOMA-IR: Homeostatic
model of assessment insulin resistance; Hp–I: Helicobacter pylori infection; NAFL: Nonalcoholic fatty liver; NASH:
Nonalcoholic steatohepatitis.
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Table 4. Independent associates of fibrosis (F0 vs. F1-3) in binary logistic regression analysis.
Independent Variables Beta Exp(Beta) p-value 95% CI for Exp(Beta)
Hp-I diagnosis
(0: Negative; 1: Positive) 3.86 47.28 0.001 4.76–469.5
Gender
(0: Women; 1: Men) 1.95 7.00 0.026 1.26–39.02
Hypertension
(0: No; 1: Yes) −0.18 0.84 0.82 0.18–3.90
Hyperglyceridemia
(0: No; 1: Yes) −0.20 0.82 0.81 0.16–4.11
Age (years) 0.05 1.05 0.08 0.99–1.12
BMI (kg/m2) −0.05 0.95 0.37 0.86–1.06
HOMA-IR −0.04 0.96 0.56 0.83–1.11
Abbreviations: BMI: Body mass index; FLI: Fatty liver inhibition of progression; HOMA-IR: Homeostatic model
of assessment insulin resistance; Hp-I: Helicobacter pylori infection; NAFL: Nonalcoholic fatty liver; NASH:
Nonalcoholic steatohepatitis.
4. Discussion
This study favors an association between active Hp-I and histological severity of NAFLD in
morbidly obese patients subjected to bariatric surgery. Specifically, higher rates of NASH, as well as
hepatic steatosis, inflammation, and fibrosis were observed in Hp(+) than Hp(−) patients, findings
warranting further investigation. Notably, Hp-I was independently positively associated with NASH,
severe NASH, and hepatic fibrosis, the latter considered as the main histological prognostic factor [36].
Importantly, the histological diagnostic “gold standard” for both main variables of interest (active
Hp-I and NAFLD) were used, which is scarce in the literature. More specifically, this is the second
study, after the study of Lecube et al. [14] investigating the association between Hp-I and NAFLD by
using both gastric and liver biopsies, in which liver biopsy was performed in a subset of patients (22%
of patients subjected to gastric biopsy). In that study, higher steatosis rates were observed in Hp(+)
patients, as in our study, but, unexpectedly rates of NASH were higher in Hp(−) patients. Moreover,
contrary to our finding, the authors reported similar overall NAFLD rates between Hp(+) and Hp(−)
patients [14]. There is no secure conclusion about the controversy of our with Lecube et al. [14] study;
population and/or methodological differences may exist, thus warranting more studies, specifically
designed to this aim.
Noteworthy, we were the first to show an association between Hp-I and NAFLD in a case-control
study of biopsy-proven NAFLD patients [37]. Subsequently, other studies reported a positive association
between Hp-I and NAFLD, including those of Yu et al. [19], Sumida et al. [38], Okushin et al. [18],
Kim et al. [10,27], Zhang et al. [21], Chen et al. [26], Dogan et al. [25], Abdel-Razik et al. [24], and
Kang et al. [11]. Noteworthy, there have been five systematic reviews performed with meta-analysis,
all of which revealed a positive association between the pathologies of interest [39–43]. Nonetheless,
there are studies showing no association between Hp-I and NAFLD [14,15,19,20,22].
The association between Hp-I and components related to IR or MetS were also investigated in this
study as secondary aims. Higher liver function tests, triglycerides, HOMA-IR, and higher rates of
arterial hypertension were observed in Hp(+) compared with Hp(−) patients. In a systematic review
we performed almost 10 years ago, we have proposed a positive association between Hp-I and IR, in
terms of HOMA-IR [44]. Although controversy still exists, similar results to this study have provided a
meta-analysis between Hp-I, MetS, and MetS-related comorbidities [45].
The observational nature of this study cannot show causality or direction of the relationship,
i.e., to answer the question whether Hp-I is another pathogenetic factor of NAFLD or, inversely,
NAFLD makes affected individuals more susceptible to Hp-I. However, pathogenetic mechanisms
between Hp-I and NAFLD may be hypothesized. Hp-I related gastrointestinal epithelium disruption,
microbiota, and their metabolites translocation into portal circulation, activation of inflammation
via toll-like receptors signaling in hepatocytes, may be some contributors linking Hp-I with the
development and progression of NAFLD [3,46]. In this regard, human β-defensin-1, possibly serving as
a biomarker of bacterial translocation in chronic liver disease, is induced by Hp-I. Hp-I also contributes
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to a low-grade inflammation by inducing the release of vasoactive and proinflammatory molecules,
including interleukin (IL)-1, IL-6, IL-8, IL-10, IL-12, tumor necrosis factor-α, interferon-γ, eicosanoids
(leukotrienes, prostaglandins), and acute phase proteins (C-reactive protein and fibrinogen), which
are implicated in the pathophysiology of IR syndrome and NAFLD. Moreover, Hp-related induction
of oxidative stress, atrophic gastritis-associated with vitamin B12/folate deficiency, apoptosis, and
the possible downregulation of adiponectin, constitute other pathogenetic links between Hp-I and
NAFLD [3,46]. Furthermore, Hp-related galectin-3 connected with MetS may play a role in the
pathophysiology of MetS-related NAFLD and its extrahepatic complications, including chronic kidney,
cardiovascular, and brain disorders; the number of galectin-3 positive liver cells is associated with
NAFLD severity; galectin-3 binding protein is a potential marker of disease; and galectin-3 inhibitors
may exhibit potential efficacy in advanced fibrosis/cirrhosis due to NASH. Finally, Hp-related MetS
conditions are associated with dysmotility-induced microbiota dysbiosis, particularly small intestinal
bacterial overgrowth (SIBO) playing a role in the pathogenesis of NAFLD; SIBO exhibits an effect on
the structural and functional issues of the liver leading to greater prevalence of NAFLD. Notably, SIBO
prevalence is higher in morbidly obese patients than in healthy populations and is connected with
severe hepatic steatosis [47]. However, further large-scale relative studies are needed to elucidate in
depth the aforementioned proposed pathogenetic mechanisms.
Although the use of both liver and gastric biopsies is a strength of this study, there are also certain
limitations. First, the retrospective nature of the study renders it susceptible to record and recall
bias. Second, as mentioned above, a cause–effect relationship cannot be shown. Third, the sample
size was small, although it was sufficient to show robust statistical significance in major endpoints.
Furthermore, information on previous use of proton pump inhibitors before obtaining gastric biopsies
was not available. Last, the duration of Hp-I, which might have affected the results, remains unknown.
5. Conclusions
This study favors an association of active Hp-I on NAFLD severity in morbidly obese patients
subjected to bariatric surgery. Most importantly, active Hp-I was independently associated with NASH
and the presence of fibrosis. These findings warrant specifically designed clinical studies on the
association between active Hp-I and NAFLD severity in obese, morbidly obese, and lean populations,
as well as mechanistic studies investigating the potential pathogenetic links.
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